Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain

European Journal of Clinical Pharmacology

Volumn 69, Issue 9, 2013, Pages 1651-1658

  De Gregori, Manuela ^a   Garbin, Giulia ^b   De Gregori, Simona ^a   Minella, Cristina E ^a   Bugada, Dario ^a   Lisa, Antonella ^c   Govoni, Stefano ^b   Regazzi, Mario ^a   Allegri, Massimo ^a,b   Ranzani, Guglielmina N ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c CNR   (Italy)

Author keywords

Genetic polymorphisms; Morphine consumption; Pharmacokinetics; Postoperative pain

Indexed keywords

CATECHOL METHYLTRANSFERASE; DNA; GLUCURONOSYLTRANSFERASE 2B7; METHIONINE; MORPHINE; OPRM1 PROTEIN; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; COMT GENE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG USE; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OPRM1 GENE; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PHARMACOGENETICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UGT2B7 GENE;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CATECHOL O-METHYLTRANSFERASE; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MORPHINE; PAIN, POSTOPERATIVE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882840256     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1523-7     Document Type: Article

References (35)

1. Pyati S, Gan TJ (2011) Perioperative pain management. CNS Drugs 21:185-211. doi: 10.2165/00023210-200721030-0000
2. Wu CL, Raja SN (2011) Treatment of acute postoperative pain. Lancet 377:2215-2225. doi: 10.1016/S0140-6736(11)60245-6
3. Allegri M, De Gregori M, Niebel T, Minella C, Tinelli C, Govoni S, Regazzi M, Braschi A (2010) Pharmacogenetics and postoperative pain: a new approach to improve acute pain management. Minerva Anestesiol 76:937-944
4. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14:135-143. doi: 10.1093/hmg/ddi013
5. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB et al (2006) Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125:216-224. doi: 10.1016/j.pain.2006.05.024
6. Dai F, Belfer I, Schwartz CE, Banco R, Martha JF, Tighioughart H et al (2010) Association of catechol-O-methyltransferase genetic variants with outcome in patients undergoing surgical treatment for lumbar degenerative disc disease. Spine J 10:949-957. doi: 10.1016/j.spinee.2010.07.387
7. Lee PJ, Delaney P, Keogh J, Sleeman D, Shorten GD (2011) Catecholamine-O-methyltransferase polymorphisms are associated with postoperative pain intensity. Clin J Pain 27:93-101. doi: 10.1097/AJP. 0b013e3181f15885
8. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I et al (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210. doi: 10.1021/bi00013a008
9. Reyes-Gibby CC, Shete S, Rakvåg T, Bhat SV, Skorpen F, Bruera E et al (2007) Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130:25-30. doi: 10.1016/j.pain.2006. 10.023
10. Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A (2011) Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 112:448-453. doi: 10.1213/ANE.0b013e318202cc8d
11. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613. doi: 10.1073/pnas.95.16.9608
12. Beyer A, Koch T, Schröder H, Schulz S, Höllt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-560. doi: 10.1111/j.1471-4159.2004.02340.x
13. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618-32624. doi: 10.1074/jbc.M504942200
14. Oertel BG, Doehring A, Roskam B, Kettner M, Hackmann N, Ferreirós N, Schmidt PH, Lötsch J (2012) Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet 21:4751-4760. doi: 10.1093/hmg/dds314
15. Uhl GR, Sora I, Wang Z (1999) The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96:7752-7755. doi: 10.1073/pnas.96.14.7752
16. Lötsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1-5. doi: 10.1016/j.pain.2006.01.010
17. Lötsch J, Geisslinger G, Tegeder I (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124:168-184. doi: 10.1016/j.pharmthera.2009.06.010
18. Duguay Y, Báár C, Skorpen F, Guillemette C (2004) A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223-233. doi: 10.1016/j.clpt.2003.10.006
19. Hammoud HA, Aymard G, Lechat P, Boccheciampe N, Riou B, Aubrun F (2011) Relationships between plasma concentrations of morphine, morphine-3-glucuronide, morphine-6-glucuronide, and intravenous morphine titration outcomes in the postoperative period. Fundam Clin Pharmacol 25:518-527. doi: 10.1111/j.1472-8206.2010.00867.x
20. Ladd LA, Kam PC, Williams DB, Wright AW, Smith MT, Mather LE (2005) Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. Br J Clin Pharmacol 59:524-553. doi: 10.1111/j.1365-2125.2005.02368.x
21. Costantini R, Affaitati G, Fabrizio A, Giamberardino MA (2011) Controlling pain in the post-operative setting. Int J Clin Pharmacol Ther 49:116-127. doi: 10.5414/CP201401
22. Momeni M, Crucitti M, De Kock M (2006) Patient-controlled analgesia in the management of postoperative pain. Drugs 66:2321-2337. doi: 10.2165/00003495-200666180-00005
23. Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S et al (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73-78. doi: 10.1016/j.pain.2005.03.032
24. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P (2008) Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 4:64. doi: 10.1186/1744-8069-4-64
25. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y et al (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1243. doi: 10.1126/science.1078546
26. Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ et al (2004) Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109:488-496. doi: 10.1016/j.pain.2004.02.027
27. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH et al (2006) Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50:787-792. doi: 10.1111/j.1399-6579.2006.01058.x
28. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH et al (2003) A pharmacogenetic study of uridine diphosphate- glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566-574. doi: 10.1016/S0009-9236(03)00053-5
29. Faura CC, Moore RA, Horga JF, Hand CW, McQuay HJ (1996) Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 11:95-102. doi: 10.1016/0885-3924(95)00148-4
30. Quigley C, Joel S, Patel N, Baksh A, Slevin M (2003) Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 17:185-190. doi: 10.1191/0269216303pm658oa
31. Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P et al (2003) Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 17:679-687. doi: 10.1191/0269216303pm835oa
32. Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML (2005) Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag 1:83-90
33. Lötsch J, Geisslinger G (2001) Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 40:485-499
34. Lötsch J (2005) Opioid metabolites. J Pain Symptom Manage 29[Suppl 5]:10-24. doi: 10.1016/j.jpainsymman.2005.01.004
35. Skarke C, Geisslinger G, Lötsch J (2005) Is morphine-3-glucuronide of therapeutic relevance? Pain 116:177-180. doi: 10.1016/j.pain.2005.06.006